Biocontrol Limited

Private Limited Company · Newbury

ActiveUnited KingdomIncorporated 1997Private Limited Company

Financial position

Accounts to 2025-12-31 · GBP · Company accounts

Net assets

−£4,607,380

Cash

—

Turnover

—

Profit / loss

£345,993

Current assets

£10,096

Creditors < 1 year

£4,617,476

Equity

−£4,607,380

Average employees

Not available

Balance-sheet trend

GBP · company

Financial statements

Selected figures from the best-ranked available filing for each period. Missing values remain unknown.

9 periods

Some figures were read by AI from scanned accounts, so small errors are possible. View the filed accounts

Reported figures	2025-12-31Company · AI-read	2024-12-31Company · AI-read	2019-12-3112 months	2018-12-3112 months	2018-01-01	2017-12-3112 months	2017-01-01	2016-12-3112 months	2016-01-01
Balance sheet
Net assets	−£4,607,380	−£4,953,373	−£4,616,222	−£4,780,232	—	−£4,491,811	—	−£4,814,267	—
Equity	−£4,607,380	−£4,953,373	−£4,616,222	−£4,780,232	−£4,491,811	−£4,491,811	−£4,814,267	−£4,814,267	−£3,881,963
Share capital	£231,311	£231,311	—	—	—	—	—	—	—
Retained earnings	−£8,354,353	−£8,700,346	—	—	—	—	—	—	—
Assets
Current assets	£10,096	£10,182	£3,348	£3,521	—	£30,906	—	£16,053	—
Cash at bank	—	—	£2,216	£2,384	—	£27,582	—	£13,532	—
Debtors	£10,096	£10,182	—	—	—	—	—	—	—
Liabilities
Creditors within one year	£4,617,476	£4,963,555	£4,619,570	£4,783,753	—	£4,522,717	—	£4,830,320	—
Net current assets	−£4,607,380	−£4,953,373	−£4,616,222	−£4,780,232	—	−£4,491,811	—	−£4,814,267	—
Assets less current liabilities	−£4,607,380	−£4,953,373	−£4,616,222	−£4,780,232	—	−£4,491,811	—	−£4,814,267	—
Profit & loss
Administrative expenses	£13,904	£12,457	—	—	—	—	—	—	—
Operating profit	£345,993	−£88,221	£164,010	−£288,421	—	£322,456	—	−£932,304	—
Profit / loss	£345,993	−£88,221	£164,010	−£288,421	—	£322,456	—	−£932,304	—
Operating costs
Audit fees	£5,150	£5,000	—	—	—	—	—	—	—
People & pay
Average employees	—	—	0	0	—	—	—	—	—
Source evidence	View filing	View filing	View filing	View filing	View filing	View filing	View filing	View filing	View filing

From the accounts

What the accounts for 2025-12-31 say about themselves, read by AI from the scanned filing.

Going concern: The auditor reported a material uncertainty about going concern
Auditor: Bishop Fleming Audit Limited
Audit opinion: Clean (unmodified)
Immediate parent: Armata Pharmaceuticals, Inc.
Ultimate parent: Armata Pharmaceuticals, Inc.
Ultimate controlling party: Armata Pharmaceuticals, Inc.
Accounts: FRS 102 Section 1A
Approved: 2026-07-13, signed by Jules Haimovitz

Borrowings (2)

August 2025 Loan · $15.0 million · 14.0% · matures on January 11, 2029. Principal and accrued interest are payable at maturity. · secured on secured by substantially all of the assets of the Company and the subsidiary guarantors
March 2025 Loan · $10.0 million · 14.0% · matures on March 12, 2026. Principal and accrued interest are payable at maturity. · secured on secured by substantially all of the assets of the Company and the subsidiary guarantors